Cybrexa Therapeutics

OverviewSuggest Edit

Cybrexa Therapeutics is a biotechnology company developing a new class of cancer therapeutics through its alphalex platform. The company aims to provide small molecule DNA repair inhibitors that directly target the tumor microenvironment.

TypePrivate
Founded2016
HQNew Haven, CT, US
Websitecybrexa.com

Latest Updates

Employees (est.) (Dec 2021)21
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Cybrexa Therapeutics

Vishwas Paralkar

Vishwas Paralkar

Chief Scientific Officer
Robert Aiello

Robert Aiello

Biology Director
Ranjit Bindra

Ranjit Bindra

Chief Scientific Advisor & Scientific Co-Founder
Arthur Decillis

Arthur Decillis

Acting Chief Medical Officer
Peter Glazer

Peter Glazer

Chief Medical Advisor & Scientific Co-Founder
Kevin Didden

Kevin Didden

Chairman
Show more

Cybrexa Therapeutics Office Locations

Cybrexa Therapeutics has an office in New Haven
New Haven, CT, US (HQ)
5 Science Park
Show all (1)

Cybrexa Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2016

Cybrexa Therapeutics total Funding

$44.4 m

Cybrexa Therapeutics latest funding size

$25 m

Time since last funding

9 months ago

Cybrexa Therapeutics investors

Cybrexa Therapeutics's latest funding round in March 2021 was reported to be $25 m. In total, Cybrexa Therapeutics has raised $44.4 m
Show all financial metrics

Cybrexa Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

92/100

SecurityScorecard logo

Cybrexa Therapeutics Online and Social Media Presence

Embed Graph

Cybrexa Therapeutics News and Updates

Cybrexa Therapeutics Announces Data Demonstrating Early Signals of Efficacy and Powerful Potential of Antigen-Independent Tumor Targeting

NEW HAVEN, Conn., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide drug conjugate (PDC) therapeutics, today announced favorable early Phase 1 data for its lead therapeutic candidate, CBX-12 (…

Cybrexa Therapeutics to Present at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

NEW HAVEN, Conn., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ Peptide Drug Conjugate (PDC) tumor targeting platform, announced today that it will present the results of a preclinical…

Cybrexa Therapeutics to Present Virtually at H.C. Wainwright 23rd Annual Global Investment Conference

NEW HAVEN, Conn., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ Peptide Drug Conjugate (PDC) tumor targeting platform, announced today that management is scheduled to deliver a virtual…

Cybrexa Therapeutics to Present at BTIG Virtual Biotechnology Conference 2021

NEW HAVEN, Conn., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ Peptide Drug Conjugate (PDC) tumor targeting platform, announced today that management is scheduled to deliver a company …

Cybrexa Therapeutics Announces Publication of Peer-Reviewed Article in NAR Cancer

CBX-12 study finds pH selectivity, stability in plasma and selectivity to tumor cells versus healthy tissue CBX-12 study finds pH selectivity, stability in plasma and selectivity to tumor cells versus healthy tissue

Cybrexa Therapeutics Appoints Stephen Basso as Chief Financial Officer

- Adds decades of pharmaceutical financial leadership as Cybrexa advances development of first therapeutic candidate - - Adds decades of pharmaceutical financial leadership as Cybrexa advances development of first therapeutic candidate -
Show more

Cybrexa Therapeutics Frequently Asked Questions

  • When was Cybrexa Therapeutics founded?

    Cybrexa Therapeutics was founded in 2016.

  • Who are Cybrexa Therapeutics key executives?

    Cybrexa Therapeutics's key executives are Vishwas Paralkar, Robert Aiello and Ranjit Bindra.

  • How many employees does Cybrexa Therapeutics have?

    Cybrexa Therapeutics has 21 employees.

  • Who are Cybrexa Therapeutics competitors?

    Competitors of Cybrexa Therapeutics include Janux Therapeutics, Bexion Pharmaceuticals and Sonnet BioTherapeutics.

  • Where is Cybrexa Therapeutics headquarters?

    Cybrexa Therapeutics headquarters is located at 5 Science Park, New Haven.

  • Where are Cybrexa Therapeutics offices?

    Cybrexa Therapeutics has an office in New Haven.

  • How many offices does Cybrexa Therapeutics have?

    Cybrexa Therapeutics has 1 office.